title: MHC class II-associated invariant chain-induced enlarged endosomal structures: a morphological study.
abstract: The major histocompatibility complex class II-associated invariant chain is believed to direct newly synthesized class II to endocytic compartments. Invariant chain synthesized at high levels in transiently transfected cells induces formation of large vesicular structures. We have examined the effect of stable expression of invariant chain in human fibroblasts by light and electron microscopy. Invariant chain expression dramatically modified endocytic compartments and induced the formation of greatly enlarged structures. These modifications were not lethal. Ultrastructurally, at least three morphologically distinct enlarged compartments could be discerned in the cells. These three compartments may represent early and late endosomes and lysosomes. Internalization of anti-invariant chain antibodies shows that invariant chain may reach the large endosomes via rapid internalization from the plasma membrane. Internalized protein remained in the enlarged vesicles for 4-6 h, indicating an invariant chain-induced delay in the pathway to lysosomes. Although the large invariant chain-induced vesicles have not yet been seen in professional antigen-presenting cells, the invariant chain-induced effects may play a role in regulating the endocytic pathway, creating a special environment for MHC class II to bind antigen.
authors.affiliation: Division of Molecular Cell Biology, University of Oslo, Oslo, Norway.
authors.forename: E
authors.initials: E
authors.lastname: Stang
authors.forename: O
authors.initials: O
authors.lastname: Bakke
mesh_terms: D000225:Adenine / Q000031:analogs & derivatives / Q000494:pharmacology; D015703:Antigens, CD / Q000032:analysis; D020126:Brefeldin A; D002460:Cell Line; D002738:Chloroquine / Q000494:pharmacology; D003517:Cyclopentanes / Q000494:pharmacology; D004705:Endocytosis; D011992:Endosomes / Q000187:drug effects / Q000276:immunology* / Q000648:ultrastructure*; D005347:Fibroblasts; D006684:HLA-DR Antigens / Q000096:biosynthesis*; D059805:HLA-DR alpha-Chains; D006801:Humans; D007150:Immunohistochemistry; D007976:Leupeptins / Q000494:pharmacology; D051907:Lysosomal Membrane Proteins; D008247:Lysosomes / Q000648:ultrastructure; D046911:Macromolecular Substances; D008562:Membrane Glycoproteins / Q000032:analysis; D017527:Receptor, IGF Type 2 / Q000032:analysis; D011994:Recombinant Proteins / Q000096:biosynthesis; D014162:Transfection
chemical_list: D015703:Antigens, CD; D003517:Cyclopentanes; D006684:HLA-DR Antigens; D059805:HLA-DR alpha-Chains; D007976:Leupeptins; D051907:Lysosomal Membrane Proteins; D046911:Macromolecular Substances; D008562:Membrane Glycoproteins; D017527:Receptor, IGF Type 2; D011994:Recombinant Proteins; D020126:Brefeldin A; C025946:3-methyladenine; D002738:Chloroquine; C032854:leupeptin; D000225:Adenine